|
1
|
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
|
Blood
|
2002
|
4.56
|
|
2
|
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
|
Blood
|
2010
|
4.52
|
|
3
|
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
|
Blood
|
2006
|
3.89
|
|
4
|
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
|
J Clin Oncol
|
2009
|
3.07
|
|
5
|
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.
|
J Clin Oncol
|
2004
|
2.98
|
|
6
|
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
|
Blood
|
2007
|
2.65
|
|
7
|
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
|
J Clin Oncol
|
2009
|
2.59
|
|
8
|
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.
|
J Clin Oncol
|
2007
|
2.35
|
|
9
|
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
|
J Clin Invest
|
2013
|
2.34
|
|
10
|
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
|
J Clin Oncol
|
2009
|
1.92
|
|
11
|
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.
|
Blood
|
2002
|
1.90
|
|
12
|
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
|
Clin Cancer Res
|
2008
|
1.85
|
|
13
|
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
|
Clin Cancer Res
|
2013
|
1.75
|
|
14
|
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
|
Lancet Oncol
|
2011
|
1.66
|
|
15
|
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.
|
J Clin Oncol
|
2002
|
1.58
|
|
16
|
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
|
Blood
|
2011
|
1.51
|
|
17
|
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
|
Blood
|
2014
|
1.47
|
|
18
|
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
|
Proc Natl Acad Sci U S A
|
2010
|
1.44
|
|
19
|
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
|
Mayo Clin Proc
|
2004
|
1.43
|
|
20
|
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
|
Blood
|
2005
|
1.24
|
|
21
|
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
|
Blood
|
2010
|
1.20
|
|
22
|
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
|
Clin Cancer Res
|
2010
|
1.16
|
|
23
|
Home endotoxin exposure and wheeze in infants: correction for bias due to exposure measurement error.
|
Environ Health Perspect
|
2006
|
1.12
|
|
24
|
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
|
Blood
|
2003
|
1.09
|
|
25
|
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
|
Cancer Res
|
2002
|
1.04
|
|
26
|
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
|
Blood
|
2002
|
1.02
|
|
27
|
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
|
Blood
|
2002
|
0.99
|
|
28
|
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
|
Am J Hematol
|
2010
|
0.98
|
|
29
|
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
|
J Clin Oncol
|
2010
|
0.98
|
|
30
|
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.
|
Br J Haematol
|
2003
|
0.96
|
|
31
|
Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
|
J Clin Oncol
|
2014
|
0.95
|
|
32
|
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
|
Clin Cancer Res
|
2009
|
0.94
|
|
33
|
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
|
Leuk Lymphoma
|
2008
|
0.94
|
|
34
|
A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.
|
Gynecol Oncol
|
2004
|
0.94
|
|
35
|
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.93
|
|
36
|
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
|
Blood
|
2013
|
0.92
|
|
37
|
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
|
Clin Cancer Res
|
2011
|
0.87
|
|
38
|
Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.
|
Blood
|
2002
|
0.86
|
|
39
|
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.
|
Blood
|
2006
|
0.84
|
|
40
|
Association of indoor nitrogen dioxide with respiratory symptoms in children: application of measurement error correction techniques to utilize data from multiple surrogates.
|
J Expo Sci Environ Epidemiol
|
2006
|
0.84
|
|
41
|
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493).
|
Blood
|
2002
|
0.83
|
|
42
|
The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium.
|
Haematologica
|
2014
|
0.82
|
|
43
|
Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
|
Transplantation
|
2002
|
0.82
|
|
44
|
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
|
Leuk Lymphoma
|
2007
|
0.81
|
|
45
|
Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).
|
Leuk Lymphoma
|
2012
|
0.80
|
|
46
|
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
|
Am J Hematol
|
2011
|
0.78
|
|
47
|
Extramedullary Waldenström macroglobulinemia.
|
Am J Hematol
|
2014
|
0.78
|
|
48
|
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
|
Br J Haematol
|
2012
|
0.76
|